Medical expert of the article
New publications
Preparations
Oziclide
Last reviewed: 03.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Oziklid is a member of the group of hypoglycemic (lowering sugar levels) antidiabetic drugs. Other trade names of the drug: Gliclazide, Amapiride, Glimax, Glimed, Diabeton, Diamicron, etc.).
Indications Oziclide
This medication is intended for the treatment of non-insulin-dependent diabetes mellitus (type II diabetes), complicated by obesity, in the absence of the ability to reduce and control blood glucose levels with a low-carbohydrate diet, exercise and weight loss. The medication also helps prevent vascular complications of this disease.
Release form
Tablets of 30 mg.
Pharmacodynamics
Due to the action of the active substance of the drug (a second-generation sulfonylurea derivative), there is stimulation of the receptors of the islet β-cells of the pancreas that secrete insulin, which leads to the release of endogenous insulin reserves.
The extrapancreatic action of all sulfonylurea derivatives consists of activating glycogen synthetase, an enzyme in muscle tissue that catalyzes the breakdown of the reserve form of glucose, glycogen. As a result of increased phosphorolysis of glycogen (in the process of which ATP is formed), its utilization in the body's tissues increases.
In addition, the active metabolite of Oziklide inhibits platelet aggregation, improves the rheological properties of blood (preventing adhesion and aggregation of platelets) and its microcirculation, which helps prevent vascular complications of type II diabetes, such as microangiopathy (including retinal damage), stroke and myocardial infarction.
Pharmacokinetics
After oral administration, Oziklid is absorbed in the gastrointestinal tract and enters the bloodstream; maximum concentration in blood plasma is observed after 6-8 hours; approximately 94% of the active substance binds to blood plasma proteins.
The drug is metabolized in the liver; metabolites are eliminated by the kidneys (with urine). The half-life of the drug's biotransformation products is about 10 hours.
[ 3 ]
Dosing and administration
Method of administration Oziklid – orally; tablets are swallowed whole, during the morning meal. Individual dosage is determined by the doctor based on blood glucose levels.
The recommended starting dose is 30 mg. The standard single dose ranges from 30 to 120 mg; the maximum daily dose of the medication is 120 mg.
During the period of using Oziklid, it is necessary to follow a low-calorie diet with limited carbohydrates (since glucose is the main metabolite of their metabolism in the body) and monitor blood glucose levels throughout the day.
[ 5 ]
Use Oziclide during pregnancy
Contraindicated.
Contraindications
Contraindications to the use of Oziklid are:
- insulin-dependent diabetes mellitus (type I diabetes);
- diabetic coma and pre-comatose state;
- diabetic ketoacidosis;
- hypersensitivity to sulfonylurea drugs;
- acute infectious diseases;
- leukopenia, thrombocytopenia and granulocytopenia;
- severe dysfunction of the liver and kidneys;
- age under 18 years.
Side effects Oziclide
Possible side effects of Oziklid are expressed in the form of: general weakness, nausea, vomiting, abdominal pain, diarrhea, constipation, allergic reaction (appearance of itchy maculopapular rashes on the skin), decreased blood sugar levels (hypoglycemia), increased levels of liver enzymes, reversible changes in the blood (anemia, leukopenia, thrombocytopenia), as well as temporary visual impairment (at the initial stage of treatment).
[ 4 ]
Overdose
In case of an overdose of Oziklid, hypoglycemic coma, convulsions, and loss of consciousness are possible, requiring emergency medical care with hospitalization.
If the person is conscious, it is necessary to give him 50 g of sugar, in case of loss of consciousness, a 40% glucose solution (50 ml) is administered intravenously (quickly). After which a drip with a 5% glucose solution is placed.
Interactions with other drugs
The use of Oziklid is incompatible with:
- ethanol and alcohol-containing drugs,
- miconazole and fluconazole,
- sulfonamides,
- tetracycline,
- nonsteroidal anti-inflammatory drugs (NSAIDs),
- indirect antithrombotic agents,
- cardiac glycosides,
- antihypertensive, antiarrhythmic and antianginal agents of the β-blocker group.
The effectiveness of Oziklid is reduced by the simultaneous use of glucocorticosteroids (including those for external use), barbiturates and diuretics. The action of Oziklid is enhanced by analgesic and antipyretic drugs of the pyrazolone group.
[ 6 ]
Storage conditions
Store in a place protected from light at a temperature of up to +25°C.
Shelf life
Shelf life: 2 years.
Attention!
To simplify the perception of information, this instruction for use of the drug "Oziclide" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.